Photocure Studies Show Blue Light Cystoscopy Cuts Recurrence, Narrows Cost Gap

Event summary

  • Two Photocure-supported studies presented at AUA 2026 demonstrate Blue Light Cystoscopy (BLC) improves detection of high-risk bladder cancer and reduces recurrence rates.
  • BLC associated with 8.5% CIS detection vs. 3.4% with white light cystoscopy (WLC) in real-world U.S. claims cohort.
  • Cost analysis shows BLC approaches net neutrality at 5 years due to lower recurrence rates, despite higher initial outpatient costs.
  • BRAVO study in Veterans Affairs system finds BLC reduces recurrence risk by 38% (HR 0.62).

The big picture

These studies reinforce BLC's role in precision medicine for bladder cancer, addressing both clinical and economic challenges in managing a disease with high recurrence rates and costly treatment regimens. The findings position Photocure to potentially expand its market share as healthcare systems seek cost-effective diagnostic solutions. The shift toward personalized medicine in urology is underscored by growing consensus around targeted diagnostic approaches.

What we're watching

Adoption Dynamics
Whether real-world cost data will accelerate BLC adoption in high-risk NMIBC management.
Competitive Positioning
How Photocure will leverage these findings to strengthen its market position against standard WLC.
Regulatory Impact
The pace at which payers may adjust reimbursement policies based on these cost-effectiveness findings.